Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

The Evolving Treatment Landscape in Paroxysmal Nocturnal Hemoglobinuria

June 29th 2023

The treatment landscape for PNH is rapidly evolving, and clinicians have more effective and convenient treatment options for patients that have helped control the disease and improve survival. T

Lisocabtagene Maraleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of TRANSCEND CLL 004

June 29th 2023

Alexey Danilov, MD, PhD, presents an analysis of data from the Phase 1 TRANSCEND CLL 004 study investigating lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib

June 28th 2023

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia

June 26th 2023

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

June 26th 2023

Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23rd 2023

The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.

New and Anticipated Advances Across Hematologic Malignancies Necessitate Improved Navigation of Current Options

June 23rd 2023

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL

June 22nd 2023

Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.

Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD Rate in CLL/SLL

June 22nd 2023

Zanubrutinib plus obinutuzumab and venetoclax demonstrated lasting responses characterized by sustained progression-free survival and undetectable minimal residual disease in peripheral blood and bone marrow in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Zanubrutinib Maintains PFS Benefit With Extended Follow-Up in Previously Untreated CLL/SLL

June 21st 2023

Extended follow-up from the phase 3 SEQUOIA trial demonstrated that zanubrutinib maintained a progression-free survival benefit compared with bendamustine plus rituximab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Study Protocol Differences May Affect BTK Inhibitor Performance in R/R CLL

June 21st 2023

Patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib in the phase 3 RESONATE trial achieved a significantly longer median progression-free survival compared with those in the phase 3 ALPINE trial, as well as a higher yet nonsignificant 2-year PFS estimate vs those in the phase 3 ELEVATE-RR trial.

Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL

June 12th 2023

Luke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with 17p deletions and TP53 mutations, and the investigation of liso-cel in patients with relapsed/refractory CLL.

Phase 3 CLL12 Data Support Watch-and-Wait Approach in Early-Stage CLL

June 11th 2023

Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.

Venetoclax Plus Rituximab Provides Long-Term Survival Benefit in Relapsed/Refractory CLL

June 11th 2023

Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.

Acalabrutinib Has Tolerable Safety Profile in Older, Frail CLL Population

June 9th 2023

Acalabrutinib is safe in patients with chronic lymphocytic leukemia who are at least 80 years of age and/or frail.

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

June 8th 2023

Acalabrutinib and zanubrutinib demonstrated similar investigator-assessed progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia.

Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL

May 27th 2023

The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.

METTL3 Controls Splicing Factor Abundance and Aids Progression in CLL

May 24th 2023

Yiming Wu, PhD, discusses the rationale for studying splicing defects in patients with chronic lymphocytic leukemia without spliceosome mutations, shared key findings from this study, and emphasized how these findings support further research with METTL3 in chronic lymphocytic leukemia and other hematologic malignancies with RNA splicing dysregulation.

China Approves Zanubrutinib in Previously Untreated CLL/SLL and Waldenström Macroglobulinemia

May 8th 2023

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in treatment-naïve adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

April 26th 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.